skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.

 

Bezerra_Lara

 

 

For someone who led Roche in Venezuela at a time when the South American nation grapples through one of its worst economic crises, Lara Bezerra’s India posting may seem like a breeze. The Swiss multinational on Nov. 14 announced that Bezerra was taking over as managing director for Roche Products (India) Pvt Ltd from Maturin Tchoumi who has moved to Roche Finland in a new role.

 

 

But Bezerra may need to stay “resilient” and “lead by example” – attributes she refered to in her online posts during her stint in Venezuela – as she steers Roche through a maze of evolving regulations and potential policy shifts in the price-sensitive Indian market. (Also see "India’s Rx Policy Shifts Could Spark Turf Wars Within Government" - Scrip, 28 Aug, 2017.) India is also heading towards a general election in 2019, which usually means that vote-bank interests rank high on the agenda of political parties.

 

 

And then there is the Swiss multinational’s high-profile and acrimonious legal battle against the Indian regulator and biosimilar players in India, where Roche has, in the past, been accused of attempting to distort competition and also disparage the reputation of biosimilars. Most of these cases are ongoing. Roche has all along maintained that it adheres to all applicable laws and regulations in countries where it operates and refuted the allegations regarding anti-competitive conduct. (Also see "Roche Faces Probe On Claims It Derailed Biosimilar Herceptin" - Scrip, 26 Apr, 2017.)

 

 

On the business front, Roche, although ranked well below peers Abbott, GlaxoSmithKline Pharmaceuticals Ltd. and Pfizer Ltd. in India, reported growth of 27.6%, albeit on a relatively small base, as per September 2017 MAT (moving annual total) data from AIOCD AWACS, the market research agency that tracks retail sales.

 

Leadership Was Critical In Navigating Turbulence

 

Bezerra, who comes with over 24 years of experience in the pharmaceutical industry, has held various positions of leadership across various geographies, including Europe and Latin America. Her LinkedIn profile indicates stints with Bayer as well, before her role as general manager of Roche Venezuela.

 

 

“Her tenure in Venezuela was among the most turbulent times in the country’s history, and her leadership was critical in navigating that period,” said a statement from Roche, which also noted that in 2016, Roche was named among the top 20 places to work in Venezuela.

 

 

Bezerra expects to build on Roche’s foundation in India by “bringing transformational medicines” to the country, being a “strong” healthcare partner and making a “meaningful difference” for patients in India.

 

 

In previous online posts, Bezerra has described herself as neither a “traditional” or “modern” person, but as someone with “lots of faith, in humanity, in countries”, which is perhaps indicative of a strong sense of awareness around balancing the old with the new and acceptance of varied thinking. In a developing but upwardly mobile country like India, which is keen to balance traditional and modern medicine and also ensure affordable access to drugs alongside encouraging the development and launch of innovative therapies, such attributes may perhaps hold her in good stead.

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topics Drug development landscape

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    By Brian Yang

    Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

    Topics Policy and regulation

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: